by The patient derived xenograft (PDX) model market involves developing and maintaining models that capture the biological and molecular diversity of human cancers for personalized cancer treatment. PDX models are developed by transplanting fresh tumor tissues directly from patients into immunodeficient mice for disease modeling and preclinical drug testing. These models help retain the genomic, histological and phenotypic characteristics of the original tumor and have become indispensable tools for precision oncology research, drug discovery and development of novel anticancer therapies.
The global PDX model market is estimated to be valued at US$ 105.4 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the patient derived xenograft model market include Aksa Akrilik Kimya Sanayii A.S.(Aksa), Dralon, Aditya Birla Group, Jilin Chemical Fibre Company, Taekwang Industrial Co., LTD, Exlan Japan Co., Ltd., Kaneka Corporation, Indian Acrylics Limited, Pasupati Acrylon Ltd., and Vardhman Acrylics Ltd. These players are focusing on expanding their catalog of PDX models and services to assist cancer researchers.
The key opportunities in the Patient Derived Xenograft Model market Demand include increasing collaboration between academics and commercial entities to develop large PDX repositories and biobanks. This will help researchers expedite translational research and drug development process. Several pharmaceutical companies are also outsourcing PDX modeling services to Contract Research Organizations (CROs) to screen and validate potential drug candidates in pre-clinical studies.
The patient derived xenograft models market is also witnessing significant growth in the Asia Pacific region owing to increasing investments by governments and private players in developing robust oncology research infrastructure. Countries like China, Japan and South Korea are emerging as major hubs for outsourced PDX modeling services.
Market drivers
A major market driver is the need for more predictive pre-clinical models to evaluate drug efficacy and safety prior to clinical trials. PDX models mimic human tumor heterogeneity better than cell line-based models and help reduce late-stage drug failures. They can accurately predict whether a drug will work in patients or not. This is driving increased adoption of PDX models in precision oncology research and development.
PEST Analysis
Political: The regulations concerning animal testing and research determine the scope of this market. Stringent regulations can limit research while supportive regulations can boost research.
Economic: Growing healthcare spending and increasing research funding are fueling demand in this market. The high cost of R&D also drives the need for cost-effective alternative models like PDX models.
Social: Growing awareness about diseases and increasing demand for personalized medicine are supporting the adoption of PDX models for developing tailored therapies. Ethical concerns about animal testing can also promote the use of PDX models.
Technological: Advancements in tumor grafting techniques, development of optimized matrices for engraftment and growth of patient tumors, and availability of associated tools and technologies are expanding the applications of PDX models.
Geographical regions where market in terms of value is concentrated:
North America region accounts for the largest share of the Patient Derived Xenograft Model Market Regional Analysisis owing to favorable government funding, presence of majorplayers, and advanced healthcare research infrastructure. Growth in this region is also favored by increasing collaborations between academic institutions and biopharmaceutical companies for translational research.
The fastest growing region for this market:
The Asia Pacific region is expected to witness the highest growth over the forecast period due to rising incidences of cancer, growing biotech and pharmaceutical industries, improving research capabilities, and increasing government support for life sciences research in major countries like China and India.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
